Implementing Best Practices in Non-Alcoholic Fatty Liver Disease

Thursday, May 12, 2022

7:00 PM – 9:00 PM

Location: Breakout Room 4-Aqua ABC (Level 3)

CME Credits: 1.5

Presenter(s)

Zobair Younossi, MD, MPH
Principal Investigator
Inova Fairfax Hospital, United States

Disclosure: Disclosure information not submitted.
Kenneth Cusi, MD, FACP, FACE
Chief of the Division of Endocrinology
UFL
Newberry, Florida, United States

Disclosure: Allergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
Rohit Loomba, MD MHSc
University of California, San Diego

Disclosure: Disclosure information not submitted.
Michael Charlton, MD
Disclosure: Disclosure information not submitted.

How to Register:
1. Log-in to your meeting dashboard at https://registration.experientevent.com/showTHY221/Flow/ATT?code=#!/registrant//Dashboard/
2. Navigate toward Registration and select “Add Ticketed Events”.
3. Next to Implementing Best Practices in Non-Alcoholic Fatty Liver Disease click “Add” to secure your ticket!

Planned by: Medscape Education
Provided by an education grant from: Siemens Healthineers

Non-alcoholic fatty liver disease (NAFLD), a condition in which excess fat is stored in the liver, is a major cause of liver disease worldwide. It affects about one quarter of the global adult population, and is expected to become the leading cause of liver-related mortality in the coming decades. Non-alcoholic Steatohepatitis (NASH) is the most serious form of NAFLD in which inflammation leads to progressive fibrosis and ultimately cirrhosis. Therefore, this makes it imperative to identify patients at risk of NASH and initiate effective treatment plans early in the disease process.  

Join our panel of top experts in this CME-certified symposium to learn more about current guideline recommendations to identify and diagnose patients at risk of developing NASH, how to assess the risk of NASH progression and liver-related events, as well as recommendations for current and emerging therapies to effectively manage these patients.  

Participants should be aware of the following financial/non-financial relationships:

Zobair Younossi, MD, MPH: Disclosure information not submitted.

Kenneth Cusi, MD, FACP, FACE: Allergan Pharmaceuticals (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); AstraZeneca (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Axcellla (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); BMS (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Boehringer Ingelheim (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Cirius (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Coherus (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Deuterex (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Echosens (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Eli Lilly (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Fractyl (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Genentech (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Genfit (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); High Tide (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Inventiva (Individual(s) Involved: Self): Grant/Research Support, Research Grant; Janssen (Individual(s) Involved: Self): Research Grant; Madrigal (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Merck (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); National Institutes of Health (Individual(s) Involved: Self): Grant/Research Support, Research Grant; Nordic (Individual(s) Involved: Self): Research Support; Novo Nordisk (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Poxel (Individual(s) Involved: Self): Research Grant; Prosciento (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Sanofi-Adventis (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Viscera Labs (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Zydus (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant

Rohit Loomba, MD MHSc: Disclosure information not submitted.

Michael Charlton, MD: Disclosure information not submitted.